Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Cash & Equivalents: 2021-2024

Historic Cash & Equivalents for Core Scientific (CORZ) over the last 4 years, with Dec 2024 value amounting to $836.2 million.

  • Core Scientific's Cash & Equivalents rose 79.21% to $453.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $453.4 million, marking a year-over-year increase of 79.21%. This contributed to the annual value of $836.2 million for FY2024, which is 1558.83% up from last year.
  • Core Scientific's Cash & Equivalents amounted to $836.2 million in FY2024, which was up 1,558.83% from $50.4 million recorded in FY2023.
  • In the past 5 years, Core Scientific's Cash & Equivalents registered a high of $836.2 million during FY2024, and its lowest value of $15.9 million during FY2022.
  • Its 3-year average for Cash & Equivalents is $300.8 million, with a median of $50.4 million in 2023.
  • Per our database at Business Quant, Core Scientific's Cash & Equivalents slumped by 86.52% in 2022 and then spiked by 1,558.83% in 2024.
  • Over the past 4 years, Core Scientific's Cash & Equivalents (Yearly) stood at $117.9 million in 2021, then tumbled by 86.52% to $15.9 million in 2022, then skyrocketed by 217.36% to $50.4 million in 2023, then surged by 1,558.83% to $836.2 million in 2024.